VALUE OF THYROID-STIMULATING-ANTIBODY DETERMINATIONS IN PREDICTING SHORT-TERM THYROTOXIC RELAPSE IN GRAVES' DISEASE

T. F. Davies, D. C. Evered, B. Rees Smith, P. P.B. Yeo, F. Clark, R. Hall

Research output: Contribution to journalArticlepeer-review

116 Scopus citations

Abstract

Thirty consecutive patients with hyper-thyroid Graves' disease received a 6-month course of antithyroid drugs. Sixteen patients relapsed within 6 months of the withdrawal of antithyroid therapy. All patients with high levels of thyroid-stimulating antibodies (TSAb) at the time of drug withdrawal relapsed within 2 months of discontinuing the antithyroid treatment while all patients with low or undetectable TSAb activity at the time of drug withdrawal remained in remission. It was not possible to predict the disease course in patients who had intermediate levels of TSAb when antithyroid therapy was stopped.

Original languageEnglish
Pages (from-to)1181-1182
Number of pages2
JournalThe Lancet
Volume309
Issue number8023
DOIs
StatePublished - 4 Jun 1977
Externally publishedYes

Fingerprint

Dive into the research topics of 'VALUE OF THYROID-STIMULATING-ANTIBODY DETERMINATIONS IN PREDICTING SHORT-TERM THYROTOXIC RELAPSE IN GRAVES' DISEASE'. Together they form a unique fingerprint.

Cite this